We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCLI
176
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.06M 0.04%
29,633
-2,148
-7% -$80.4K
STML
177
DELISTED
Stemline Therapeutics, Inc.
STML
$1.06M 0.04%
+98,050
New +$797K
OCRX
178
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.06M 0.04%
400,035
-24,000
-6% -$60K
PCRX icon
179
CALL
Pacira BioSciences
PCRX
$1.04B
$1.06M 0.04%
+309
New +$12.1K
RDUS
180
CALL
DELISTED
Radius Health, Inc.
RDUS
$1.05M 0.04%
195
+38
+24% +$1.93K
CALA
181
DELISTED
Calithera Biosciences, Inc
CALA
$1.05M 0.04%
+16,225
New +$1.05M
TRAW icon
182
Traws Pharma
TRAW
$7.34M
$1.04M 0.04%
+70
New +$1.43M
ADYX
183
DELISTED
Adynxx Inc
ADYX
$1.03M 0.04%
22,029
-2,971
-12% -$184K
CVM icon
184
CEL-SCI Corp
CVM
$19.9M
$1.03M 0.04%
4,497
-6,388
-59% -$2.16M
DRWI
185
DELISTED
DragonWave Inc
DRWI
$1.02M 0.04%
+378,338
New +$1.28M
VTVT icon
186
vTv Therapeutics
VTVT
$124M
$969K 0.04%
3,369
-125
-4% -$30.1K
IMMU
187
DELISTED
Immunomedics Inc
IMMU
$966K 0.04%
297,310
-127,690
-30% -$357K
CSBR icon
188
Champions Oncology
CSBR
$75.9M
$905K 0.03%
538,593
-8,135
-1% -$15.1K
ONSIW
189
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$905K 0.03%
902,050
+475,866
+112% +$216K
TVTX icon
190
PUT
Travere Therapeutics
TVTX
$5.17B
$897K 0.03%
401
-4,425
-92% -$84.2K
PALI icon
191
Palisade Bio
PALI
$341M
$892K 0.03%
2
-4
-67% -$1.26M
RDHL
192
Redhill Biopharma
RDHL
$4.15M
$888K 0.03%
64
-84
-57% -$1.17M
DXTR
193
DELISTED
Dextera Surgical Inc.
DXTR
$851K 0.03%
450,507
-31,493
-7% -$67K
HZNP
194
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$839K 0.03%
463
– –
KPRX icon
195
Kiora Pharmaceuticals
KPRX
$11.4M
$834K 0.03%
94
+22
+31% +$236K
ITCI
196
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$812K 0.03%
533
-840
-61% -$34K
WINT
197
DELISTED
Windtree Therapeutics Inc
WINT
$797K 0.03%
310,000
-138,509
-31% -$301K
GNMX
198
DELISTED
Aevi Genomic Medicine Inc
GNMX
$791K 0.03%
141,977
+3,200
+2% +$18.2K
ARMP icon
199
Armata Pharmaceuticals
ARMP
$168M
$782K 0.03%
3,724
-660
-15% -$152K
RDUS
200
PUT
DELISTED
Radius Health, Inc.
RDUS
$763K 0.03%
141
+21
+18% +$1.07K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.